GNPX: Genprex Inc. Company Value to Net Income

Genprex Inc. - graphic logo of issuer GNPX

The price history of Genprex, Inc. (GNPX) reflects the asset's dynamics, with a current value of -0.10. Genprex, Inc. (GNPX) leads in gene therapy, focusing on the ONCOPREX platform to combat diabetes and treating lungs with the drug REQORSA. Success relies on non-contact gene delivery and synergy with immunotherapy, while robotic biochemical screening accelerates preclinical tests by minimizing human error.

Price to Earnings Ratio: Genprex, Inc. (GNPX) for 07/04/2022 - 11/12/2026

Comprehensive metric breakdowns and analytics for Genprex, Inc (GNPX)

- share price and expert price forecast:
Price Performance Chart genprex.com|GNPX - Consensus Target
- market capitalization information:
Market Value Genprex, Inc.|GNPX - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share Genprex|GNPX - Company Net Assets|Market Capitalization to Book Value Ratio genprex.com|GNPX - Aggregate Company Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Genprex, Inc.|GNPX - Long-Term Debt to Capital|Current Liabilities to Capital Genprex Inc|GNPX - Company Aggregate Debts|Debt to Net Assets Genprex, Inc.|GNPX - Company Long-Term Debts|Short-Term Debt Genprex|Immediate Liquidity Ratio genprex.com
- company profitability and valuation multiples indicators:
GNPX - Company Net Income|Forward Earnings Genprex, Inc.|GNPX - Price to Earnings Ratio|Future Price to Earnings Multiple Genprex Inc.|GNPX - PEG Multiple|Company Value to EBITDA Genprex, Inc.|GNPX - Operating profit before deduction of amortization|Earnings per share for the last 12 months Genprex|GNPX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months genprex.com|GNPX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Genprex, Inc.
Summary company analysis:GNPX - genprex.com
Flagship merchandise of Genprex

For Genprex, Inc., which focuses on obtaining FDA approval for innovative gene therapies, the P/E ratio reflects current investor expectations regarding future profits from cancer and diabetes treatments. This metric compares the market value of a share with the net income per share, allowing the P/E ratio analysis to determine the extent of the premium paid for the business potential and its long-term sustainability.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Company Value to Net Income|P/E Multiple AAPG (Ascentage)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis (PSNL) - Price to Earnings Ratio|Erasca Inc - Company Value to Net Income|DCTH (Delcath) - P/E Multiple|Market Cap to Earnings Y-mAbs Corp YMAB|P/E Multiple AURA|candeltx.com (CADL) - Market Cap to Net Income Ratio|P/E Multiple ARAY (Accuray)|SELLAS Life Sciences Group, Inc. (SLS) - Market Cap to Earnings|ACTU - Price to Earnings Ratio|CTOR (Citius Oncology Inc) - Price to Earnings Multiple|tuhurabio.com (HURA) - Price to Earnings Ratio|Market Cap to Net Income TARA (protaratx.com)|Price to Earnings Ratio Fate Therapeutics|WHWK: Company Value to Net Income|P/E Multiple TCRX|CSBR - Market Cap to Earnings|XBiotech - Price to Earnings Ratio|CVM: Price to Earnings Multiple|OSTX: Price to Earnings Ratio|Company Value to Net Income RADX (radiopharmtheranostics.com)|ARTV: P/E Multiple|ANL - Business Payback Period|Price to Earnings Ratio Veru Inc.|Price to Earnings Multiple TPST (tempesttx.com)|P/E Multiple XLO|Price to Earnings Ratio renovarobio.com RENB|Mural Oncology - Price to Earnings Ratio|Business Payback Period Kairos Pharma Limited (KAPA)|OnKure - P/E Multiple|Market Cap to Net Income Ratio CytoMed Therapeutics (GDTC)|curis.com (CRIS) - Price to Earnings Ratio|Price to Earnings Multiple APLM|Price to Earnings Ratio Tharimmune Corp|Advanced Biomed Corp - Market Cap to Net Income|Price to Earnings Ratio CLDI (Calidi Biotherapeutics)|sunshinebiopharma.com - Price to Earnings Multiple|P/E Multiple XBIO (Xenetic Biosciences, Inc.)|SLRX - Price to Earnings Ratio|Purple Biotech Corp - P/E Multiple|AONC - P/E Multiple|BeiGene, Ltd. (BGNE) - Price to Earnings Ratio|Price to Earnings Multiple CKPT|ELEV (Elevation Oncology) - P/E Multiple|Price to Earnings Ratio iCAD Corp (ICAD)|P/E Multiple IKNA|NTBL - Market Cap to Earnings|Price to Earnings Ratio Viracta Therapeutics, Inc. VIRX|Company Value to Net Income MOR|NAYA: Price to Earnings Ratio|Company Value to Net Income AAPGV (Ascentage Pharma Group International)